HRP20120793T1 - Kristalni oblici nilotinib hci - Google Patents

Kristalni oblici nilotinib hci Download PDF

Info

Publication number
HRP20120793T1
HRP20120793T1 HRP20120793AT HRP20120793T HRP20120793T1 HR P20120793 T1 HRP20120793 T1 HR P20120793T1 HR P20120793A T HRP20120793A T HR P20120793AT HR P20120793 T HRP20120793 T HR P20120793T HR P20120793 T1 HRP20120793 T1 HR P20120793T1
Authority
HR
Croatia
Prior art keywords
theta
degrees
nilotinib hcl
ppm
chemical shift
Prior art date
Application number
HRP20120793AT
Other languages
English (en)
Croatian (hr)
Inventor
Greta Sterimbaum
Sigalit Levi
Adi Yeori
Tamas Koltai
Valerie Niddam-Hildesheim
Maytal Piran
Shay Asis
Hagit Eisen-Nevo
David Malcolm Crowe
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120793(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20120793T1 publication Critical patent/HRP20120793T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Exhaust Gas Treatment By Means Of Catalyst (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
HRP20120793AT 2008-11-05 2009-11-05 Kristalni oblici nilotinib hci HRP20120793T1 (hr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US11156108P 2008-11-05 2008-11-05
US15578909P 2009-02-26 2009-02-26
US17745409P 2009-05-12 2009-05-12
US22721009P 2009-07-21 2009-07-21
US24070909P 2009-09-09 2009-09-09
US24251409P 2009-09-15 2009-09-15
US24679909P 2009-09-29 2009-09-29
US24937609P 2009-10-07 2009-10-07
PCT/US2009/063365 WO2010054056A2 (en) 2008-11-05 2009-11-05 Nilotinib hci crystalline forms

Publications (1)

Publication Number Publication Date
HRP20120793T1 true HRP20120793T1 (hr) 2012-12-31

Family

ID=41666779

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120793AT HRP20120793T1 (hr) 2008-11-05 2009-11-05 Kristalni oblici nilotinib hci

Country Status (12)

Country Link
US (2) US8227477B2 (enExample)
EP (2) EP2530081A3 (enExample)
JP (1) JP5486012B2 (enExample)
KR (2) KR20120111743A (enExample)
CN (1) CN102203084B (enExample)
CA (1) CA2740794A1 (enExample)
DK (1) DK2262793T3 (enExample)
ES (1) ES2394258T3 (enExample)
HR (1) HRP20120793T1 (enExample)
PL (1) PL2262793T3 (enExample)
TW (1) TW201022240A (enExample)
WO (1) WO2010054056A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2010KO00035A (enExample) * 2010-01-15 2016-09-02
US20110263701A1 (en) * 2010-04-21 2011-10-27 Sigal Blau Gabapentin enacarbil compositions
CN103038227A (zh) * 2010-06-21 2013-04-10 特瓦制药工业有限公司 尼洛替尼盐及其晶形
HRP20151324T1 (hr) 2010-06-21 2016-01-29 Teva Pharmaceutical Industries, Ltd. Soli nilotiniba i njihovi kristalni oblici
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
IN2011CH01887A (enExample) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
EP2626355B1 (en) * 2012-02-09 2016-02-03 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
CA2888002A1 (en) * 2012-10-15 2014-04-24 Apotex Inc. Solid forms of nilotinib hydrochloride
MX2015004947A (es) * 2012-10-19 2016-02-22 Basf Se Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
NZ714378A (en) 2013-04-24 2020-08-28 Dr Reddys Laboratories Ltd Polymorphic forms of nilotinib hydrochloride
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
EP3177610A4 (en) 2014-08-08 2018-01-10 Dr. Reddy's Laboratories Ltd. Process for the preparation of polymorphic forms of nilotinib
WO2016058081A1 (en) 2014-10-16 2016-04-21 Apotex Inc. Solid forms of nilotinib hydrochloride
CN106478603B (zh) * 2015-08-25 2021-01-01 江苏豪森药业集团有限公司 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
HUE050890T2 (hu) 2016-03-14 2021-01-28 Pliva Hrvatska D O O Nilotinib sók szilárd halmazállapotú formái
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
US20240316044A1 (en) 2021-06-19 2024-09-26 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CN101228150B (zh) * 2005-07-20 2014-10-15 诺华股份有限公司 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
FR2889524B1 (fr) 2005-08-05 2008-08-29 Rhodia Chimie Sas Procede de formation d'une liaison carbone-azote
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof

Also Published As

Publication number Publication date
US8227477B2 (en) 2012-07-24
KR101251726B1 (ko) 2013-04-05
EP2262793A2 (en) 2010-12-22
CN102203084B (zh) 2014-10-29
US20130096304A1 (en) 2013-04-18
EP2262793B1 (en) 2012-10-03
KR20120111743A (ko) 2012-10-10
PL2262793T3 (pl) 2013-01-31
WO2010054056A2 (en) 2010-05-14
EP2530081A2 (en) 2012-12-05
US20100190812A1 (en) 2010-07-29
JP5486012B2 (ja) 2014-05-07
EP2530081A3 (en) 2013-04-10
JP2012508178A (ja) 2012-04-05
CN102203084A (zh) 2011-09-28
US8592442B2 (en) 2013-11-26
KR20100099257A (ko) 2010-09-10
DK2262793T3 (da) 2012-10-15
ES2394258T3 (es) 2013-01-30
WO2010054056A3 (en) 2010-09-16
CA2740794A1 (en) 2010-05-14
TW201022240A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
HRP20120793T1 (hr) Kristalni oblici nilotinib hci
HRP20151324T1 (hr) Soli nilotiniba i njihovi kristalni oblici
HRP20121028T1 (hr) Kristalni oblici febuksostata
ES2524380T3 (es) Sales de raltegravir y formas cristalinas de las mismas
HRP20130458T4 (hr) MALATNA SOL OD N-(4-{[6,7-BIS(METILOKSI)KINOLIN-4-IL]OKSI} FENIL-N'-(4-FLUOROFENIL)CIKLOPROPAN-1,1-DIKARBOKSAMIDA I NJEZINI KRISTALNI OBLICI ZA LIJEČENJE RAKA\n
CR8248A (es) Forma cristalina beta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
HRP20161742T1 (hr) Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
ME02800B (me) Nova triciklična jedinjenja
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
HRP20160654T1 (hr) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
HRP20140667T1 (hr) Nukleozid fosforamidat prolijekovi
BRPI0600796A (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
IL193395A0 (en) Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
EP2580225A4 (en) BENZYL BENZENOL SGLT2 HEMMER CRYSTALLINE FORM
HRP20230081T1 (hr) Kristalni monohidratni kompleks od 1-cijano-2-(4-ciklopropil-benzil)-4-(beta-d-glukopiranoz-1-il)-benzena i l- prolina u kristalnoj vodi (1:1:1), postupci za njegovu pripravu i njegova uporaba kao sglt inhibitora
AR056931A1 (es) Forma cristalina gamma d del clorhidrato de ivabradina, un procedimiento para su preparacion, composiciones farmaceuticas que la contienen, y usos en trastornos cardiovasculares
JP2014526498A5 (enExample)
HRP20150356T1 (hr) Kristalni oblici soli prasugrela
ME02655B (me) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
HRP20241280T1 (hr) Kruti oblici rukapariba i soli rukapariba
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
WO2007099216A3 (fr) FORME CRISTALLINE β DU SEL D'ARGININE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
JP2015506941A5 (enExample)
WO2008081041A3 (en) Amorphous and crystalline forms of rivastigmine hydrogentartrate
AR083256A1 (es) Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico